High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

Study summary

The purpose of the study is to evaluate the feasibility and acceptability of a dietary intervention (FEED-FF) that includes fermented foods (FF), among locally advanced rectal cancer patients and non-small cell lung cancer (NSCLC) patients, and to explore whether this diet can improve outcomes in rectal cancer patients receiving chemoradiation and NSCLC patients receiving immunotherapy.

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedFEED-FF and Standard of Care (SUC)

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 23, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?H. Lee Moffitt Cancer Center and Research Institute

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Not applicable
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Interventions being studied: Other: FEED-FF; Other: Standard of Care (SUC)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Locally advanced→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

for GI Patients:
18 years of age or older
Diagnosed with locally advanced rectal cancer (Stage II-III)
Will undergo neoadjuvant chemoradiation at Moffitt Cancer Center
Able to pick up FFs once/weekly at Moffitt
Able to speak and read English
Able to consume foods orally
Able to provide informed consent Inclusion Criteria for Thoracic Patients:
18 years of age or older
Diagnosed with stage II-IV non-small cell lung cancer (NSCLC)
Will undergo Immunotherapy with immune checkpoint inhibitors (+/- chemotherapy or other treatment) at Moffitt Cancer Center
Able to pick up FFs once/weekly at Moffitt
Able to speak and read English
Able to consume foods orally
Able to provide informed consent

Reasons someone may not be able to joinExclusion criteria

Antibiotic use within 1 month prior to baseline
If currently using probiotics, unwillingness to cease probiotic use
Previous receipt of surgery, immunotherapy, chemotherapy, or radiation for a colon or rectal tumor
Per clinician's discretion, clinician confirmed inflammatory bowel conditions (e.g., ulcerative colitis, Crohn's disease)
Infectious disease diagnosed \<1 month prior to baseline
Already consuming ≥2 servings of fermented foods/day
Previously diagnosed with a mast cell disorder or histamine allergy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Moffitt Cancer CenterTampa, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 23, 2026. Always confirm current availability with the study team.

View original record ↗